NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vasomune Therapeutics

Vasomune Therapeutics

Private
TorontoHealthcare & Life Scienceshttps://vasomune.com/

Last Round

Strategic

Nov 25, 2025

Total Funding Raised

$14.75M

Company Overview

Vasomune Therapeutics is a biotechnology company that develops novel therapeutics for diseases associated with vascular dysfunction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalvascular-targeted therapyTie2 receptor agonistvascular leakageendothelial dysfunctionacute respiratory distress syndromeARDSclinical-stage biotechdrug developmentvascular medicinesmall-molecule drugcritical care therapeuticstranslational researchbiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vasomune Therapeutics Comparables

Compare Vasomune Therapeutics with similar companies based on industry and business-model similarity.

Vasomune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AnGes, Inc.
83%
Adrenomed AG
78%
Aqualung Therapeutics Corporation
77%

Vasomune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 25, 2025
Series AJan 1, 2023
GrantNov 8, 2021
GrantNov 8, 2021
GrantAug 18, 2020
Seed
Oct 20, 2014

Key People

Founding team and executive leadership

Brian Jahns

President, and Chief Executive Officer

Executive Team

Vasomune Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 7, 2024

    Grew 50% QoQ from 6 to 9 employees.

  • Nov 8, 2021

    $2.21M grant received from NRC IRAP.

Vasomune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vasomune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vasomune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto
Employee Range11
Year Founded2014
Last FundingNov 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.